Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Follow-Up Questions
Qui est le CEO de Immunovant Inc ?
Dr. Eric Venker est le Chief Executive Officer de Immunovant Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action IMVT ?
Le prix actuel de IMVT est de $25.21, il a increased de 2.15% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Immunovant Inc ?
Immunovant Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Immunovant Inc ?
La capitalisation boursière actuelle de Immunovant Inc est de $4.3B
Est-ce que Immunovant Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 16 analystes ont établi des notations d'analystes pour Immunovant Inc, y compris 8 achat fort, 9 achat, 5 maintien, 0 vente et 8 vente forte
